We explored the relationship between time to relapse and different exposure variables (serum methotrexate (S-MTX) 23, 36 and 42 h after start of administration, MTX elimination time and leucovorin (LV) dose) during high-dose MTX (HDM) treatment of 445 children with acute lymphoblastic leukemia. MTX was infused at 5 g/m 2 (non-high risk) or 8 g/m 2 (high risk) over 24 h, 2-9 times per patient. LV rescue dose was adjusted according to the S-MTX concentration. Time from end of the last HDM to relapse was analyzed by Cox regression analysis with the logarithms of S-MTX and LV dose as exposures. The combined results from all risk groups suggest that high LV dose is related to higher risk for relapse. Doubling of the LV dose increased the relapse risk by 22% (95% confidence interval 1-49%, P ¼ 0.037). High LV doses correlated with high MTX levels at 23, 36 and 42 h and longer elimination time. The results suggest that high doses of LV increase the risk for relapse despite the fact that they were correlated with high MTX levels and longer MTX elimination time. The choice of MTX and LV doses may be regarded as an intricate balance between effect and counter-effect.
Introduction
Methotrexate (MTX) is used for treating a variety of different leukemias and solid tumors in children and adults. In combination with folinic acid as an antidote, high doses may be administered. This approach may overcome cellular drug resistance and improve penetration into pharmacological sanctuaries. 1 Although high-dose MTX (HDM) has been used for treating childhood acute lymphoblastic leukemia (ALL) for more than 30 years, the optimal way to administer HDM remains to be established. Most commonly, MTX is administered as a 24 h infusion with leucovorin (LV) administered after 36-42 h and continued until plasma MTX is below 0.1-0.25 mM. Several studies have indicated that the end-infusion MTX concentration is related to the chances of cure, [2] [3] [4] although this has been questioned by others. 5 Most convincingly, Evans et al. 6 in a randomized study demonstrated that individual dose adjustment of MTX to obtain an MTX concentration within a target range increased the cure rate significantly for B-lineage ALL. In addition, the duration of MTX exposure above a critical threshold may be relevant as well. 7, 8 In contrast, the clinical significance of LV dosage has received little attention, although both in vitro 9, 10 and in vivo studies 8, [11] [12] [13] have indicated that higher doses of LV or earlier administration may be related to a higher risk of relapse probably by rescuing malignant cells from the effect of HDM.
In the present study, we have explored the relation between relapse rates obtained from the Nordic Society of Paediatric Haematology and Oncology (NOPHO) database and end of infusion serum MTX (S-MTX) concentrations (MTX 23 ), and LV dosage for patients treated with 5 or 8 g MTX/m 2 /24 h according to the NOPHO 92 ALL protocol. We have also examined the relation between relapse rates and S-MTX concentrations 36 h (MTX 36 ) and 42 h (MTX 42 ) after infusion start and duration of MTX exposure.
Materials and methods
Data on practically all children with ALL in the Nordic countries are registered in a central NOPHO database, from which basic demographic and prognostic information and follow-up data in the present study are obtained.
14 Detailed data on treatment (e.g. MTX concentrations, LV doses, dates and times) are not included in this database and were collected from the patient records. In Denmark, Norway and Sweden, treatment data were obtained from a subcohort of the NOPHO register, whereas in Finland a nested case-control study design was used for this purpose.
The patients were classified into risk groups determined by age and white blood cell (WBC) counts (standard risk (SR), 2-10 years, WBCo10 Â 10 9 /l; intermediate risk (IR) 1-o2 or X10 years and/or WBC ¼ 10-49 Â 10 9 /l; high risk/very high risk (HR/ VHR), WBC X50 Â 10 9 /l), T-cell disease, a mediastinal mass, t(9;22), t(4;11), and the presence of central nervous system or testicular leukemia, lymphomatous leukemia, or an M3 bone marrow day 15 or a M2 bone marrow day 29 (all HR/VHR criteria).
14 Treatment for each patient was determined by the risk group classification.
From January 1992 to December 1997, 1018 children over 1 year of age were diagnosed with non-B-cell childhood ALL and treated according to the NOPHO ALL-92 protocol in Sweden, Denmark and Norway. Thirty-seven centers from these countries participated in the cohort study and submitted data on S-MTX) concentrations and LV doses from 2853 HDM treatments in 460 of those 1018 patients.
Out of the 460 patients, 31 were not treated according to NOPHO protocols and hence were excluded. For those patients who completed the scheduled HDM treatments, we have studied the relationship between the different exposure variables (S-MTX 23, 36 and 42 h after start of administration, MTX elimination time and LV dose) and time to relapse. Thus, followup from 1 month after the last HDM was studied in a landmark analysis and all 10 patients who developed a relapse before this time were excluded from the study.
The remaining 419 eligible patients had similar characteristics as the rest of the patients diagnosed with ALL in Sweden, Denmark and Norway during the same period of time regarding age, gender and WBC at diagnosis, immune phenotype and risk grouping ( Table 1 ). The patients in the cohort part were followed up until 31 December 2001.
Owing to lack of resources, it was not possible to perform a cohort study in Finland. Therefore, a nested case-control study was initiated with patients from the university hospitals in Helsinki and Oulu. Children who developed a relapse before 31 December 1996 were eligible by the same inclusion criteria as those in the other three countries. In addition, we randomly selected two control patients for each relapsed patient. The controls were matched according to hospital, risk group classification, age at diagnosis and length of follow-up. A total of nine cases and 17 controls from Finland were included (one case only had one control).
Treatment
According to the risk group classification, 14 The entire treatment protocol has been described previously by Gustafsson et al.
14
As part of the NOPHO ALL-92 maintenance therapy study, 317 of the children were randomly assigned to have their oral mercaptopurine (MP)/MTX maintenance therapy adjusted by WBC and red blood cell levels of 6-thioguanine nucleotides (the cytotoxic metabolites of MP) and MTX (pharmacology group) or by WBC only (control group) as previously reported. 15 
HDM treatment
According to the protocol, 10% of the MTX dose should be infused during the first hour and the remaining 90% over the following 23 h. Intravenous (i.v.) hydration was stipulated to 3000 ml/m 2 /24 h and increased to 4500 ml/m 2 /24 h if S-MTX 36 h after infusion start was X3 mM. Urinary pH should be measured at every voiding. NaHCO 3 Table 2 .
According to the protocol, the same LV dose should thereafter be given unchanged every 6 h, until S-MTX had reached a level o0.2 mM. However, at some centers, an elevated dose of folinic acid was reduced with falling MTX concentrations, especially in more recent years.
S-MTX was analyzed using enzyme multiplied immunoassay technique (Behring Diagnostics, Syva Business, San Jose, CA, USA) or fluorescence polarization immunoassay (Abbot Scandinavia AB, Solna, Sweden).
Median values (lower-upper quartile) and number of patients for which the examined parameters were obtained are given in Table 3 in relation to risk group and relapse. Table 1 Distribution of patients in the SR, IR, HR and VHR groups in the cohort, background material and case-controls ) after start of MTX infusion. The dose of LV should be adjusted as shown in the table. According to the protocol, the same LV dose should thereafter be given unchanged every 6 h until 6 h after S-MTX had reached a level o0.2 mM. However, at some centers, an elevated dose of folinic acid was reduced with falling MTX concentrations, especially in more recent years.
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Statistical design and analysis
The primary aim of the study is to investigate the effect of MTX concentration and LV dose on relapse and death in children treated according to the NOPHO ALL-92 protocol. Only patients who have fulfilled all scheduled courses are considered, and the primary end point is time from end of complete MTX treatment to the first of the events ALL relapse and death of any cause, or to end of follow-up (31 December 2001), that is, relapse-free survival (RFS). As there is a large variation in MTX concentrations and LV doses, both within and between patients, we have generally used logarithmized values to describe and analyze the effect of these exposures. The effect of the logarithmized exposures on RFS is analyzed using a combination of Cox regression, stratified on risk group, for the cohort part, and conditional logistic regression for the case-control part, assuming constant relative risks within risk groups for the patients in both the cohort and the case-control part of the study. As in standard Cox regression and conditional logistic regression, the relative risks are estimated by means of the maximum likelihood method. The combined likelihood may be maximized straightforwardly using a standard program for stratified Cox regression analysis, with the risk groups in the cohort and the case-control sets as separate strata.
Using logarithmized exposures, it is assumed that the relative risk is the same between exposures that differ by a constant factor. For simplicity, we use logarithms with base 2 and present relative risks associated with doubling a concentration or dose.
Two exposures are central in the study, MTX concentration at 23 h and LV dose, and we have considered both the values of the first course and, separately, the medians over courses (within patients). Univariate analyses as well as analyses with two factors at a time have been carried out, both per risk group and stratified for all the material. The heterogeneity over risk groups of the effect of the exposures was tested by likelihoodratio tests.
Information on the potential confounding factors age, sex, weight, immunophenotype, leukocyte number at diagnosis and HDM treatment time period (from start of the first HDM to 1 month after start of the last HDM) was available, and the analyses for all the material were repeated including these factors, one at a time, to see if this changed the effect of the two main study factors.
A large portion of the children took part in the NOPHO ALL-92 maintenance therapy study, 15 and several treatments and other parameters were repeatedly determined: thiopurine methyltransferase activity, MTX and 6-thioguanine nucleotide levels in erythrocytes, WBC, lymphocyte count, absolute neutrophil count, MTX maintenance dose and MP maintenance dose. For two of the risk groups, IR and SR, the maintenance study started before the end of the HDM treatment period, and for these two groups the confounding effects of the above parameters were evaluated analogously to the other potential confounders. For each parameter, the average of all measurements before the end of the HDM treatment (i.e. start of risk time in the present study) was determined, and the analyses in the IR and SR groups combined were repeated with these means as covariates, one at a time, to see how the relative risks studied were affected.
To illustrate the data, Kaplan-Meier curves of RFS, using only the cohort data, are presented by risk group, and for values over and below median exposures within the respective risk group.
Results
Although considerable efforts were made to obtain a more complete material, a substantial amount of data could not be retrieved; for example, in the various risk groups, 12-17% of the data on MTX 23 was missing. Furthermore, there was a pronounced intraindividual variability for both LV dose and MTX 23 . For MTX 23 , the median within-patient s.d. was about 30% of the respective individual geometric mean value in the SR, IR and HR groups, whereas it was 10% in the VHR group. For the LV dose, the median s.d. was 30-60% of the geometric mean value in all the risk groups.
There was a slight correlation between patient log LV dose and log MTX 23 In Figures 3 and 4 , median LV dose and MTX 23 , respectively, are plotted vs course number for relapsed and non-relapsed Table 3 Median (lower-upper quartile) and number of patients for which the examined parameters were obtained in relation to SR, IR, HR and VHR groups and relapse Tables 4 and 5 . As can be seen in Figure 3 , the median LV dose in the relapsed patients is higher than in the relapse-free patients in all courses in both the HR and IR groups. In the SR patients, this was observed only in course numbers 1 and 3. In the VHR group, the LV doses in the relapsed patients were slightly lower than in those without relapse in both the HDM courses given. Correspondingly, the median LV dose of all courses was higher in patients with relapse in the IR and HR groups as opposed to the SR and VHR groups ( Table 3) . As seen in Figure 4 , the MTX 23 in the relapsed patients was higher than in the relapse-free patients in all courses in the HR group and in all courses except number 5 in the IR group. In contrast, the MTX 23 values were higher in relapse-free patients in all courses except course number 5 in the SR group. In the VHR group, the MTX 23 values in the relapsed patients were similar to those without relapse in both the HDM courses given. Correspondingly, the median MTX 23 value of all courses was higher in relapse-free patients in the SR group as opposed to the HR and IR groups (Table 3) . Table 4 shows the results from univariate pooled Cox and conditional logistic regression analyses with 2 log MTX 23 and the 2 log LV dose value from the first course and the median of all courses as covariates.
The combined results from all risk groups suggest that high LV doses are related to higher risk for relapse both when the first course value (P ¼ 0.02) and the median value (P ¼ 0.037) were The combined results from all risk groups did not indicate any significant correlation between MTX 23 levels and relapse. However, in the SR group, high MTX 23 appears to be related to higher survival both when the first course (P ¼ 0.003) and median values from all courses (Po0.001) in each patient were analyzed. The corresponding relative risks when doubling MTX 23 were 0.54 and 0.26 for the first course and median values, respectively (i.e. the risk is reduced by 46 and 74%, respectively). In contrast, high median MTX 23 levels seem to increase risk for relapse in the other risk groups. This heterogeneity between risk groups was significant; P ¼ 0.049 and P ¼ 0.001 for the first course and the median over courses, respectively.
The pattern was essentially unchanged when both MTX 23 and LV dose were analyzed together in multivariate analyses ( Table 5) .
The effects of MTX 23 and LV dose were unchanged when adjusting for the potential confounding factors age, sex, weight, immune phenotype, WBC at diagnosis and HDM treatment time period in the analyses (data not shown). The correlation between HDM treatment time period and LV dose or MTX 23 was low.
For those IR and SR patients who were also included in the NOPHO-92 ALL maintenance therapy study, baseline information regarding several treatment and other parameters is known.
When adjusting the main analyses for these factors, one at a time, the MTX 23 and LV dose relative risks only changed marginally. For instance, in this patient group, the unadjusted relative risks when doubling the median LV dose and MTX 23 were 2.81 (95% confidence interval (CI) 1.71-4.61) and 0.31 (95% CI 0.13-0.76), respectively, in a two-dimensional analysis. When adjusting for the maintenance therapy study parameters, one at a time, the above relative risks varied in the intervals 2.16-2.84 and 0.28-0.43, respectively. RFS in the cohort part is illustrated with Kaplan-Meier curves in Figure 5a according to individual LV doses (median over courses) above and below respective risk group median doses. Corresponding curves for MTX 23 are given in Figure 5b .
Correlation analyses demonstrated a high correlation (correlation coefficients 0.65-0.95) between 2 log LV dose and 2 log MTX 36 , 2 log MTX 42 and 2 log MTX elimination time during course 1 (Figure 1) , and similar correlations were obtained for medians over courses (data not shown). Therefore, the results of univariate regression analyses on those variables largely mirrored those obtained for 2 log LV dose, that is, generally high values tended to increase the relapse risk.
Discussion
The results suggest that high LV doses during HDM increase the risk for relapse in children treated for ALL according to the NOPHO 92 ALL protocol. The negative influence of high LV Leucovorin, methotrexate and relapse risk in childhood ALL TVCh Skärby et al Table 4 Univariate Cox and conditional logistic regression analyses with 2 log MTX 23 and 2 log LV dose value from the first course and the median of all courses as covariates Table 5 Multivariate Cox and conditional logistic regression analyses with the two factors 2 log LV and 2 log MTX 23 as covariates using data from the first course and the median over courses, respectively 
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TVCh Skärby et al doses on relapse was obtained despite the fact that they correlated with high MTX levels at 23, 36 and 42 h and longer elimination time, which, everything else alike, are expected to give a better prognosis. Overdosing of LV appears to overcome the presumed beneficial effects of high MTX concentrations. In the SR group, high MTX 23 concentration was related to lower risk for relapse, whereas in the other risk groups it was rather related to higher relapse risk.
Neither MTX 23 nor LV dose appeared to have a major impact on RFS in the VHR group. It is reasonable to assume that the impact of the two HDM courses is more limited in this risk group where HDM is a relatively smaller part of the total treatment as compared to the other risk groups, where the HDM treatment is a more pronounced part of the treatment protocol. Therefore, a possible influence of MTX 23 levels and/or LV dose may be more difficult to detect in the VHR group. This is, to our knowledge, the largest material analyzed regarding the influence of MTX concentrations and LV dose on RFS during HDM. However, it has several limitations. Firstly, detailed data on treatment is somewhat incomplete, as it was only possible to retrieve 85% of the requested data. However, the impact of missing data was reduced by using within-patient median values, as they are relatively robust, and by using data from the first course, which had the least amount of missing data. Neither the missing data nor the fact that inclusion of patients was not carried out prospectively is expected to cause a bias in the material, as the exposure data were all registered in the patient records before follow-up. Secondly, the impact on relapse by MTX concentration and LV dose over time may be quite complex and, most probably, other models could describe the relations somewhat different from those used in the present study. By necessity, a simple model must be used and our choice certainly is influenced by the data, underlining the hypothesis-generating character of the study. The intraindividual variability in MTX concentrations and LV doses was quite large, making it more difficult to extract a single representative exposure value.
Thirdly, a bias may occur if high LV doses were confounded with some other risk factor, but we have not been able to identify such a relationship. Thus, the results were not affected when the analyses of all the material were adjusted, one by one, for a number of potential confounders. A large portion of the children participated in the NOPHO ALL-92 maintenance therapy study, 15 and for the IR and SR groups, who started the maintenance therapy before the end of HDM therapy, several treatment and other parameters were available at baseline. None of these was found to be a confounder.
As pointed out, for example, by Nygaard and Schmiegelow, 16 toxicity following HDM may cause reduction of dose intensity and survival rate. HDM-induced toxicity may also be related to long MTX elimination time and high LV doses. However, as the correlation between HDM treatment time period and LV dose is low, the effect of high LV dose is unlikely to be a reflection of low dose intensity. The patient population analyzed appears to be representative of the whole population of patients diagnosed with ALL in Sweden, Denmark and Norway during the same period of time, as they had similar characteristics (Table 1) 14 ). The present results agree well with previous studies in vivo on osteosarcoma 11 and ALL 8, 12, 13 and in vitro, 9, 10 indicating that higher doses of LV may be related to higher risk for relapse, probably by rescuing malignant cells from the effect of MTX. In fact, already in 1948, Farber et al. 17 described an 'acceleration phenomenon' in the leukemic process as seen in the marrow and viscera of children with ALL treated by injection of folic acid conjugates.
In the study on 108 children by Evans et al., 2 it was found that a steady-state concentration of MTX o16 mM is related to an increased risk for relapse in children with ALL. Borsi and Moe 3 presented results on 58 patients, suggesting that children with relapse had higher systemic clearance. Similarly, in 80 children with ALL, Camitta et al. 4 observed relapse in 20 of 34 patients with mean end-infusion MTX levels below 11 mM, whereas only five of 37 children with corresponding MTX concentrations above 11 mM relapsed. In contrast, in a study on 42 patients, Seidel et al. 5 could not demonstrate that the clearance of MTX had any influence on RFS. Using concentration-guided individualized MTX dosing in 182 children, Evans et al. 6 reduced the relapse incidence as compared to the conventionally dosed (by body surface area) group. Thus, although not unequivocal, these previous studies [2] [3] [4] 6 have suggested that higher end-infusion MTX concentrations were related to lower risk for relapse. In the present study, such a relationship was found only in the SR group. It is not easily understood why high MTX 23 levels are not related to better outcome in the other risk groups in our study. A possible explanation for the different impact on outcome of MTX 23 and LV doses in the SR/IR and HR group might be their different frequency of high-hyperdiploid ALL and T-cell disease. Thus, it is well known that high-hyperdiploid ALL has a high propensity and that T-cell disease has a low propensity for MTX polyglutamation. [18] [19] [20] [21] High-hyperdiploid ALL is characterized by a median age of 3-4 years and a low white cell count at Leucovorin, methotrexate and relapse risk in childhood ALL TVCh Skärby et al diagnosis, and would thus preferentially be grouped as SR patients, whereas all T-cell patients were classified in the HR/ VHR group. Thus, it is possible that low S-MTX concentration would be most crucial in the SR group, whereas high LV doses would be most deleterious in the HR group.
Although the mechanisms involved are not completely understood, the present results have had impact on the design of the new protocol for treatment of ALL in the Nordic countries (NOPHO ALL 2000) with a lowering of the LV dose as compared to the previous protocol. There is no reason to believe that the results are not applicable to other types of cancer in which HDM is included in the treatment. The results suggest that choosing MTX and LV doses may be regarded as an intricate balance between effect and counter-effect, and that LV doses should be reduced as much as possible without intolerable toxic side effects. Although discordant with the conclusion by Cohen 22 this is congruent with the findings by Mantadakis et al. 23 that the uptake of MTX in relation to folate by leukemic lymphoblasts in vitro may correlate positively with treatment outcome in children with ALL. It is also in agreement with the conclusion by Boarman et al. 9 that competition between MTX and LV occurs at the level of dihydrofolate reductase through a competitive interaction with dihydrofolate. The impact of LV dose on relapse is clinically important and it would be of value if already existing material from other groups could be analyzed in a similar fashion to further illuminate the question. However, owing to the complex relations between MTX concentrations, LV doses and risk of relapse, a prospective randomized clinical trial comparing RFS after different LV doses during HDM would probably be necessary to settle the issue.
